|
|
LETTER TO THE EDITOR |
|
|
|
Year : 2013 | Volume
: 45
| Issue : 2 | Page : 204 |
|
Author's reply
Narendranath Sanji1, Padmanabha Kaimar2, Madhusudan Upadya2, K Riaz Mohammed2
1 Department of Pharmacology, JJM Medical College, Davangere, Karnataka, India 2 Department of Anaesthesiology, Kasturba Medical College, Mangalore, Karnataka, India
Date of Web Publication | 11-Mar-2013 |
Correspondence Address: Narendranath Sanji Department of Pharmacology, JJM Medical College, Davangere, Karnataka India
 Source of Support: None, Conflict of Interest: None  | Check |

How to cite this article: Sanji N, Kaimar P, Upadya M, Mohammed K R. Author's reply. Indian J Pharmacol 2013;45:204 |
Sir,
We thank the readers for the queries raised for our article. Our replies to these queries are as follows:
- The control group included normotensive patients (ASA-1) and the study group consisted of hypertensive patients on antihypertensives (ASA-2).
- The hypertensive patients included in the study were on antihypertensives for at least 2 weeks prior to surgery. The increased requirement of mephentermine in patients on CCBs was an incidental finding at the end of the study, when the results were being analyzed. As far as the upper age limit and the inclusion of equal number of females in all the three groups are concerned, it could not be implemented because of various practical constraints.
- Regarding the query on exclusion criteria, all the mentioned factors were considered before including the patients for the study.
- The antihypertensive drugs were administered on the day of surgery.
- Pre anaesthetic medications were not used in the study.
- The association between heart rate and hypotension was not analyzed. A heart rate of 50/min was considered as bradycardia, because in this institute the practice is that atropine is injected when the heart rate drops to 50/min.
- Regarding the drop in blood pressure, it is 30% from the baseline, but by pure oversight it is mentioned as 20% at one place.
- We regret this error, made by oversight.
- We have mentioned these findings as they are relevant to the drug groups under evaluation in our study.
- The data obtained could benefit the frail patients where the anticipated changes in BP and HR could help avert these complications.
|
 |
|
|
|
|